TCRX
TScan Therapeutics, Inc.
+0.02 (+7.07%)0.35USD731K成交股數–市值–本益比(近四季)–股價營收比-65.8%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.1M-66% | 982K-55% | 2.6M+145% | 2.5M+368% | 3.1M+443% | 2.2M-70% | 1.0M-73% | 536K-83% | 566K | 7.2M | 3.9M | 3.1M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 23.4M | 21.9M | 20.0M | 31.7M | 32.6M | 29.8M | 26.3M | 26.9M | 24.9M | 22.4M | 22.7M | 21.2M |
| 銷售管理費用 | 8.1M | 8.2M | 6.4M | 7.9M | 9.1M | 8.6M | 7.4M | 7.8M | 7.1M | 6.2M | 5.9M | 6.5M |
| 營業利益 | −30.5M-21% | −29.1M-20% | −23.9M-27% | −37.1M+9% | −38.7M+23% | −36.3M+70% | −32.6M+32% | −34.1M+39% | −31.4M | −21.4M | −24.7M | −24.6M |
| 營業利益率 | -2,901.3% | -2,967.3% | -929.4% | -1,475.6% | -1,256.6% | -1,669.7% | -3,109.8% | -6,364.6% | -5,542.9% | -296.2% | -636.7% | -781.8% |
| 稅後淨利 | −30.4M-18% | −28.7M-16% | −23.0M-23% | −35.7M+13% | −37.0M+23% | −34.1M+74% | −29.9M+30% | −31.7M+32% | −30.1M | −19.6M | −23.0M | −24.0M |
| 淨利率 | -2,888.6% | -2,919.1% | -895.1% | -1,422.1% | -1,201.3% | -1,571.9% | -2,849.1% | -5,906.9% | -5,325.4% | -272.0% | -591.6% | -763.8% |
| 稀釋 EPS | -0.23-18% | -0.22-15% | -0.18-28% | -0.280% | -0.28-12% | -0.26-181% | -0.25+4% | -0.28-45% | -0.32 | 0.32 | -0.24 | -0.51 |
| 稀釋股數 | 130M | 130M | 130M | 130M | 130M | 130M | 119M | 113M | 94.9M | 65.6M | 94.8M | 47.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 100M | 128M | 152M | 170M | 169M | 154M | 133M | 242M | 141M | 133M | 155M | 209M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | 31.9M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 171M | 202M | 229M | 262M | 299M | 333M | 348M | 375M | 241M | 272M | 291M | 317M |
| 有息負債 | 21.1M | 32.7M | 32.5M | 32.4M | 32.3M | 32.2M | 30.6M | 20.1M | 23.4M | 26.7M | 28.8M | 29.7M |
| 總負債 | 102M | 105M | 106M | 118M | 122M | 123M | 119M | 120M | 118M | 121M | 122M | 126M |
| 股東權益 | 69.0M | 96.9M | 123M | 144M | 177M | 210M | 229M | 255M | 123M | 151M | 169M | 191M |
| 負債比 | 59.7% | 52.0% | 46.2% | 45.1% | 40.8% | 36.8% | 34.2% | 31.9% | 48.9% | 44.6% | 42.0% | 39.9% |
| 淨現金(現金 − 有息負債) | 79.1M | 95.4M | 120M | 137M | 137M | 122M | 102M | 222M | 117M | 107M | 126M | 179M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −24.3M-35% | – | – | – | −37.6M | – | – | −29.3M | – | – | – |
| 資本支出 | – | 70K | – | – | – | 1.5M | – | – | 705K | – | – | – |
| 自由現金流 | – | −24.3M-38% | – | – | – | −39.1M | – | – | −30.0M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -2,479.5% | – | – | – | -1,801.8% | – | – | -5,295.4% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 10.3M
| Reportable | 10.3M | 100.0% | +266.7% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 10.3M | +266.7% | −130M | -1,256.8% | -1.00 | −140M |
| FY2024 | 2.8M | -86.6% | −127M | -4,527.7% | -1.14 | −115M |
| FY2023 | 21.0M | +55.5% | −89.2M | -423.9% | -1.36 | −64.5M |
| FY2022 | 13.5M | +33.5% | −66.2M | -489.3% | -2.75 | −70.7M |
| FY2021 | 10.1M | +834.7% | −48.6M | -479.5% | -4.17 | −58.6M |
| FY2020 | 1.1M | – | −26.1M | -2,408.0% | -28.52 | −7.3M |